Invita D3 (Colecalciferol)

Colecalciferol, the active ingredient in Invita D3, is a vitamin D analog presented as an oral tablet for oral use. It helps correct vitamin D deficiency and supports normal bone mineralization in children and adults.

GNH USA supplies Invita D3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Invita D3 (colecalciferol) is used to address conditions related to insufficient vitamin D and bone health.

Vitamin D deficiency: restores adequate serum 25‑hydroxyvitamin D levels to support calcium homeostasis. Osteomalacia and rickets prevention: provides the necessary vitamin D to promote proper bone mineralization in at‑risk populations. Bone health support: contributes to maintenance of normal bone density and reduces risk of fractures in adults.

Colecalciferol may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset that resolves after continued use. - Constipation: occasional difficulty passing stool. - Hypercalcemia symptoms: mild fatigue or headache. - Dry mouth: transient sensation of oral dryness. - Muscle cramps: occasional mild cramping.

Serious or Rare Side Effects: - Hypercalcemia: severe elevation of blood calcium causing confusion or cardiac arrhythmia. - Kidney stones: formation of calcium‑containing calculi in the urinary tract. - Allergic reaction: rash, itching, or swelling of the face, lips, or tongue. - Severe vomiting: persistent vomiting requiring medical attention.

Before using Invita D3, consider the following precautions to ensure safe and effective therapy. - Assess baseline vitamin D status: measure serum 25‑hydroxyvitamin D levels to guide supplementation. - Monitor calcium levels: periodic testing recommended for patients at risk of hypercalcemia. - Adjust dose in renal impairment: patients with severe kidney disease may require lower doses. - Caution in sarcoidosis or granulomatous disease: these conditions can increase conversion to active vitamin D. - Avoid concurrent high‑dose calcium supplements: may exacerbate hypercalcemia risk. - Store at room temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Colecalciferol can influence or be influenced by other medicines. Interactions are grouped by clinical significance.

Major Interactions (Avoid): - Thiazide diuretics: may increase risk of hypercalcemia. - Vitamin A excess: combined high intake can lead to hypercalcemia. - Lithium: vitamin D may raise lithium levels, requiring monitoring. - High‑dose calcium supplements: synergistic effect on calcium load. - Antacids containing aluminum or magnesium: may reduce absorption of vitamin D.

Moderate Interactions (Monitor Closely): - Corticosteroids: can reduce vitamin D effectiveness, may need dose adjustment. - Anticonvulsants (e.g., phenytoin, phenobarbital): increase vitamin D metabolism, potentially lowering levels. - Orlistat: may decrease absorption of fat‑soluble vitamins including vitamin D. - Cholestyramine: can bind vitamin D and reduce its bioavailability. - Bisphosphonates: concurrent use may affect calcium balance, monitor serum calcium.